Base-case cost utility analysis
In the complete case analysis (CCA), the incremental cost for the spironolactone group (n=118) compared with the no active systemic treatment group (n=101) was £125.36 (95% CI £111.13 to £139.58) (unadjusted this was £125.53 (95% CI £112.15 to £138.91)) (The CEACs (Cost-effectiveness acceptability curve (CEAC), complete case analysis, adjusted and unadjusted QALYs. ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years.